• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用背景膜成像技术对生物制剂中的亚可见颗粒进行定性高通量分析。

Qualitative High-Throughput Analysis of Subvisible Particles in Biological Formulations Using Backgrounded Membrane Imaging.

机构信息

Dosage Form Design & Development, Biopharmaceuticals Development, R&D, AstraZeneca, Gaithersburg, USA.

Dosage Form Design & Development, Biopharmaceuticals Development, R&D, AstraZeneca, Gaithersburg, USA.

出版信息

J Pharm Sci. 2022 Jun;111(6):1605-1613. doi: 10.1016/j.xphs.2022.03.010. Epub 2022 Mar 19.

DOI:10.1016/j.xphs.2022.03.010
PMID:35318031
Abstract

High-throughput analysis of low-volume samples for detection of subvisible particles (SVPs) in biologic formulations remains an unmet need in the pharmaceutical industry. Some commonly used methods, such as light obscuration and microflow imaging, for SVP analysis are not high throughput and require significant amounts of sample volume, which may impede the collection of SVP data when therapeutic protein amounts are limited, typically during early stages of formulation development. We evaluated backgrounded membrane imaging (BMI) as an orthogonal method for SVP analysis and identified critical experimental parameters. Protein concentration, sample viscosity, and membrane coverage area had to be adjusted for each sample, especially those with high protein concentrations. A comparative analysis of particle counts obtained from BMI, light obscuration, and microflow imaging for five protein samples revealed that particle counts obtained with BMI were significantly higher than those acquired with the other two techniques for all particle size categories. BMI could not accurately count particles in protein-containing samples, as the image analysis software could not accurately trace the boundaries of translucent particles. Based on our results, BMI could be used as an orthogonal method for particle characterization when sample material is limited, such as during the early stages of formulation development or screening.

摘要

高通量分析生物制剂中低体积样品中的亚可见颗粒 (SVPs) 仍然是制药行业未满足的需求。一些常用的 SVP 分析方法,如光遮挡和微流成像,不是高通量的,需要大量的样品体积,当治疗性蛋白数量有限时,这可能会阻碍 SVP 数据的收集,通常在制剂开发的早期阶段。我们评估了背景膜成像 (BMI) 作为 SVP 分析的正交方法,并确定了关键的实验参数。必须针对每个样品调整蛋白浓度、样品粘度和膜覆盖面积,特别是那些蛋白浓度高的样品。对五种蛋白样品的 BMI、光遮挡和微流成像获得的颗粒计数进行比较分析表明,对于所有粒径类别,BMI 获得的颗粒计数明显高于其他两种技术获得的颗粒计数。BMI 无法准确地对含有蛋白的样品中的颗粒进行计数,因为图像分析软件无法准确地追踪半透明颗粒的边界。基于我们的结果,当样品材料有限时,例如在制剂开发或筛选的早期阶段,BMI 可以用作颗粒特征的正交方法。

相似文献

1
Qualitative High-Throughput Analysis of Subvisible Particles in Biological Formulations Using Backgrounded Membrane Imaging.使用背景膜成像技术对生物制剂中的亚可见颗粒进行定性高通量分析。
J Pharm Sci. 2022 Jun;111(6):1605-1613. doi: 10.1016/j.xphs.2022.03.010. Epub 2022 Mar 19.
2
Backgrounded Membrane Imaging (BMI) for High-Throughput Characterization of Subvisible Particles During Biopharmaceutical Drug Product Development.背景膜成像(BMI)在生物制药药物产品开发过程中用于高通量分析亚可见颗粒。
J Pharm Sci. 2020 Jan;109(1):264-276. doi: 10.1016/j.xphs.2019.03.024. Epub 2019 Mar 23.
3
Separation, Characterization and Discriminant Analysis of Subvisible Particles in Biologics Formulations.生物制剂配方中亚可见颗粒的分离、表征及判别分析
Curr Pharm Biotechnol. 2019;20(3):232-244. doi: 10.2174/1389201020666190214100840.
4
A comparison of background membrane imaging versus flow technologies for subvisible particle analysis of biologics.生物制品亚可见粒子分析中背景膜成像与流动技术的比较。
Int J Pharm. 2020 Mar 30;578:119072. doi: 10.1016/j.ijpharm.2020.119072. Epub 2020 Jan 27.
5
Effect of solution properties on the counting and sizing of subvisible particle standards as measured by light obscuration and digital imaging methods.溶液性质对通过光阻法和数字成像法测量的亚可见颗粒标准品计数和粒径测定的影响。
Eur J Pharm Sci. 2014 Mar 12;53:95-108. doi: 10.1016/j.ejps.2013.12.014. Epub 2013 Dec 23.
6
Micro-flow imaging multi-instrument evaluation for sub-visible particle detection.用于亚可见颗粒检测的微流成像多仪器评估
Eur J Pharm Biopharm. 2023 Apr;185:55-70. doi: 10.1016/j.ejpb.2023.01.017. Epub 2023 Jan 25.
7
Label-free flow cytometry analysis of subvisible aggregates in liquid IgG1 antibody formulations.液体IgG1抗体制剂中亚可见聚集体的无标记流式细胞术分析
J Pharm Sci. 2014 Jan;103(1):90-9. doi: 10.1002/jps.23782. Epub 2013 Nov 11.
8
Subvisible Particle Analysis of 17 Monoclonal Antibodies Approved in China Using Flow Imaging and Light Obscuration.使用流动成像和光阻法对中国批准的17种单克隆抗体进行亚可见颗粒分析。
J Pharm Sci. 2022 Apr;111(4):1164-1171. doi: 10.1016/j.xphs.2021.09.021. Epub 2021 Sep 20.
9
Combining Machine Learning and Backgrounded Membrane Imaging: A Case Study in Comparing and Classifying Different Types of Biopharmaceutically Relevant Particles.结合机器学习和背景膜成像:在比较和分类不同类型的生物制药相关颗粒中的案例研究。
J Pharm Sci. 2022 Sep;111(9):2422-2434. doi: 10.1016/j.xphs.2022.05.022. Epub 2022 Jun 1.
10
Calculating the mass of subvisible protein particles with improved accuracy using microflow imaging data.利用微流成像数据更精确地计算亚可见蛋白质颗粒的质量。
J Pharm Sci. 2015 Feb;104(2):536-47. doi: 10.1002/jps.24156. Epub 2014 Oct 9.

引用本文的文献

1
Biophysical Analysis of Therapeutic Antibodies in the Early Development Pipeline.处于早期研发阶段的治疗性抗体的生物物理分析
Biologics. 2024 Dec 21;18:413-432. doi: 10.2147/BTT.S486345. eCollection 2024.
2
Rationalizing mAb Candidate Screening Using a Single Holistic Developability Parameter.使用单一整体可开发性参数合理化单克隆抗体候选物筛选
Mol Pharm. 2025 Jan 6;22(1):181-195. doi: 10.1021/acs.molpharmaceut.4c00829. Epub 2024 Dec 16.
3
Approaches to expand the conventional toolbox for discovery and selection of antibodies with drug-like physicochemical properties.
拓展具有类药性理化性质的抗体的发现和筛选的常规工具包的方法。
MAbs. 2023 Jan-Dec;15(1):2164459. doi: 10.1080/19420862.2022.2164459.